

CERTIFICATION OF ENROLLMENT

SUBSTITUTE SENATE BILL 5027

Chapter 259, Laws of 2015

64th Legislature
2015 Regular Session

PRESCRIPTION DRUG MONITORING DATABASE--ACCESS--CLINICAL LABORATORIES

EFFECTIVE DATE: 7/24/2015

Passed by the Senate April 16, 2015
Yeas 42 Nays 2

BRAD OWEN

President of the Senate

Passed by the House April 8, 2015
Yeas 77 Nays 20

FRANK CHOPP

Speaker of the House of Representatives

Approved May 14, 2015 11:35 AM

JAY INSLEE

Governor of the State of Washington

CERTIFICATE

I, Hunter G. Goodman, Secretary of the Senate of the State of Washington, do hereby certify that the attached is **SUBSTITUTE SENATE BILL 5027** as passed by Senate and the House of Representatives on the dates hereon set forth.

HUNTER G. GOODMAN

Secretary

FILED

May 14, 2015

**Secretary of State
State of Washington**

SUBSTITUTE SENATE BILL 5027

AS AMENDED BY THE HOUSE

Passed Legislature - 2015 Regular Session

State of Washington 64th Legislature 2015 Regular Session

By Senate Health Care (originally sponsored by Senators Angel, Darneille, Dammeier, Keiser, Parlette, Cleveland, Bailey, and Chase)

READ FIRST TIME 02/10/15.

1 AN ACT Relating to providing access to the prescription drug
2 monitoring database for clinical laboratories; amending RCW
3 70.225.040; and adding new sections to chapter 70.225 RCW.

4 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF WASHINGTON:

5 **Sec. 1.** RCW 70.225.040 and 2011 1st sp.s. c 15 s 87 are each
6 amended to read as follows:

7 (1) Prescription information submitted to the department
8 (~~shall~~) must be confidential, in compliance with chapter 70.02 RCW
9 and federal health care information privacy requirements and not
10 subject to disclosure, except as provided in subsections (3) and (4)
11 of this section.

12 (2) The department (~~shall~~) must maintain procedures to ensure
13 that the privacy and confidentiality of patients and patient
14 information collected, recorded, transmitted, and maintained is not
15 disclosed to persons except as in subsections (3) and (4) of this
16 section.

17 (3) The department may provide data in the prescription
18 monitoring program to the following persons:

19 (a) Persons authorized to prescribe or dispense controlled
20 substances, for the purpose of providing medical or pharmaceutical
21 care for their patients;

1 (b) An individual who requests the individual's own prescription
2 monitoring information;

3 (c) Health professional licensing, certification, or regulatory
4 agency or entity;

5 (d) Appropriate local, state, and federal law enforcement or
6 prosecutorial officials who are engaged in a bona fide specific
7 investigation involving a designated person;

8 (e) Authorized practitioners of the department of social and
9 health services and the health care authority regarding medicaid
10 program recipients;

11 (f) The director or director's designee within the department of
12 labor and industries regarding workers' compensation claimants;

13 (g) The director or the director's designee within the department
14 of corrections regarding offenders committed to the department of
15 corrections;

16 (h) Other entities under grand jury subpoena or court order;
17 ((and))

18 (i) Personnel of the department for purposes of administration
19 and enforcement of this chapter or chapter 69.50 RCW; and

20 (j) Personnel of a test site that meet the standards under
21 section 2 of this act pursuant to an agreement between the test site
22 and a person identified in (a) of this subsection to provide
23 assistance in determining which medications are being used by an
24 identified patient who is under the care of that person.

25 (4) The department may provide data to public or private entities
26 for statistical, research, or educational purposes after removing
27 information that could be used to identify individual patients,
28 dispensers, prescribers, and persons who received prescriptions from
29 dispensers.

30 (5) A dispenser or practitioner acting in good faith is immune
31 from any civil, criminal, or administrative liability that might
32 otherwise be incurred or imposed for requesting, receiving, or using
33 information from the program.

34 NEW SECTION. Sec. 2. A new section is added to chapter 70.225
35 RCW to read as follows:

36 (1) Test sites that may receive access to data in the
37 prescription monitoring program under RCW 70.225.040 must be:

38 (a) Licensed by the department as a test site under chapter 70.42
39 RCW; and

1 (b) Certified as a drug testing laboratory by the United States
2 department of health and human services, substance abuse and mental
3 health services administration.

4 (2) Test sites may not:

5 (a) Charge a fee for accessing the prescription monitoring
6 program;

7 (b) Store data accessed from the prescription drug monitoring
8 program in any form, including, but not limited to, hard copies,
9 electronic copies, or web/digital based copies of any kind. Such data
10 may be used only to transmit to those entities listed in RCW
11 70.255.040(3)(a).

12 NEW SECTION. **Sec. 3.** A new section is added to chapter 70.225
13 RCW to read as follows:

14 (1) Access to data in the qualifying laboratory must be under the
15 supervision of the responsible person as designated by the United
16 States department of health and human services, substance abuse and
17 mental health services administration certification program.

18 (2) Such data cannot be gathered, shared, sold, or used in any
19 manner other than as designated under RCW 70.255.040, section 2 of
20 this act, or this section.

Passed by the Senate April 16, 2015.

Passed by the House April 8, 2015.

Approved by the Governor May 14, 2015.

Filed in Office of Secretary of State May 14, 2015.